Successful Launches, Upcoming Conference Calls, Signing of Agreements, and Trial Results - Research Report on Vertex, Illumina, Alexion, VIVUS, and Endocyte

Wed Oct 16, 2013 8:01am EDT

* Reuters is not responsible for the content in this press release.

Successful Launches, Upcoming Conference Calls, Signing of Agreements, and Trial Results - Research Report on Vertex, Illumina, Alexion, VIVUS, and Endocyte

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 16, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Illumina, Inc. (NASDAQ: ILMN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), VIVUS, Inc. (NASDAQ: VVUS), and Endocyte, Inc. (NASDAQ: ECYT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Vertex Pharmaceuticals Incorporated Research Report  

On October 10, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced that the Company will release its Q3 2013 financial results on Tuesday, October 29, 2013, before the financial markets open. Vertex informed that it will also host a conference call and webcast on the same day at 8:30 a.m. EDT, to discuss the results, as against the previously stated time of 5:00 p.m. EDT. The Company stated that the conference call will be webcast live and a link to the webcast will be available under "Vertex Events" of  its website, while a replay of the conference call and webcast will be archived on the Company's website until November 5, 2013. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/e696_VRTX]

--

Illumina, Inc. Research Report

On October 9, 2013, Illumina, Inc. (Illumina) announced that it has launched an advanced high-throughput screening (HTS) array format that significantly increases the number of samples that can be processed on the Infinium BeadChip family of genotyping arrays. Christian Henry, Senior Vice President and General Manager of Genomic Solutions at Illumina said, "We're excited to introduce this new array format as it enables our customers to perform larger, more powerful studies that enhance discovery. The 24-sample HTS BeadChip strengthens Illumina's leading position in the array market and further demonstrates our ability to continue innovation on our array platform, providing customers with high-quality, high-throughput genotyping solutions. The new format allows us to offer breakthrough pricing per sample which is important to enable direct-to-consumer, biobanking, basic research, and agricultural applications." The Full Research Report on Illumina, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/3cf2_ILMN]

--

Alexion Pharmaceuticals, Inc. Research Report

On October 10, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that it will report its Q3 2013 (period ended September 30, 2013) financial results on Thursday, October 24, 2013, before the US financial markets open. The Company informed that it will also host a conference call on the same day at 10:00 a.m. ET, to discuss the results and the audio web cast of the call will be available at Alexion's website. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4619_ALXN]

--

VIVUS, Inc. Research Report  

On October 11, 2013, VIVUS, Inc. (VIVUS) announced that it has signed an agreement with Auxilium Pharmaceuticals, Inc., (Auxilium) wherein the latter will have the exclusive rights to market the STENDRA (avanafil) - an oral therapy for the treatment of erectile dysfunction, in the US and Canada. VIVUS informed that the Companies have also simultaneously signed a Commercial Supply Agreement according to which VIVUS will be responsible for the manufacture and supply of STENDRA to Auxilium for a mutually agreed term. According to the license agreement, VIVUS will receive up to $300 million based on certain regulatory and sales milestones, including an upfront licensing fee of $30 million and a $15 million payment contingent upon a potential label amendment regarding onset-of-action, along with royalties on product sales. VIVUS stated that Auxilium expects to start commercial launch of STENDRA by the end of 2013.Timothy E. Morris, Senior Vice President, Finance and Global Commercial Development, CFO for VIVUS said, "The Agreement with Auxilium in the U.S. and Canada, along with the previously-announced license agreement with Menarini for Europe and abroad, fulfills significantly our objective of monetizing avanafil. Both deals combined have the potential to generate over $95 million in cash to VIVUS within the first year, in addition to royalties earned on sales of avanafil." The Full Research Report on VIVUS, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8ae9_VVUS]

--

Endocyte, Inc. Research Report  

On October 11, 2013, Endocyte, Inc. (Endocyte) announced the outcomes of the planned independent Data Safety Monitoring Board (DSMB) review of the interim futility analysis for the Phase 2b TARGET trial with investigational candidate, vintafolide. The Company stated that the DSMB has recommended the continuation of the vintafolide combination therapy and docetaxel monotherapy arms of the trial. Besides, DSMB recommends that investigators and patients be advised that vintafolide monotherapy is not likely to be declared superior to docetaxel in progression-free survival (PFS) at the end of the study, and patients currently on vintafolide monotherapy may continue treatment based on guidance from the investigator. Endocyte expects top-line results from the TARGET trial in early 2014. Binh Nguyen, M.D., Ph.D., Vice President of clinical development at Endocyte said, "The DSMB's recommendation to allow for continued treatment in the vintafolide single-agent arm enhances our opportunity to gain important information about single agent efficacy and safety to inform future trials." The Full Research Report on Endocyte, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fdf5_ECYT]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.